TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12234896

Group type: EXPERIMENTAL
Intervention: 100% O(2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 97.5% O(2) + 2.5% CO(2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 95% O(2) + 5% CO(2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 92% O(2) + 8% CO(2)
Number of subjects: 12
Study: 9852936

Group type: EXPERIMENTAL
Intervention: Ambulation at 3 hours
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Ambulation at 4 hours
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Ambulation at 6 hours
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Late hematoma formation
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Physician variation
Number of subjects: 874
Study: 7723267

Group type: COMPARATOR
Intervention: Traditional treatment (emergency operation in peritonitis or nonoperative management with cleansing enema, purgatives, and infusion-transfusion therapy)
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Emergency colonoscopy and ultrasonic diagnosis with fractional oral treatment using 30% solution of polyethylene oxide-400 and 1% chloramphenicol
Number of subjects: 532
Study: 2521934

Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg x2/day for 2 weeks, then 10 mg x2/day)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 31660826

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic AUC‐based chemotherapy
Number of subjects: 153

Group type: COMPARATOR
Intervention: BSA guided chemotherapy
Number of subjects: 153
Study: 30511130

Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene suture buttress-reinforced pancreaticojejunostomy (PBRP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional pancreaticojejunostomy (TP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PBRP
Number of subjects: 0

Group type: COMPARATOR
Intervention: TP
Number of subjects: 0
Study: 29025830

Group type: EXPERIMENTAL
Intervention: Exercise plus SCT education (SCT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Exercise plus attention control education (CON)
Number of subjects: 65
Study: 25927504

Group type: EXPERIMENTAL
Intervention: High-load strength training
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study: 23390210

Group type: EXPERIMENTAL
Intervention: Mobile Epilepsy Educational System (MEES) with text messages
Number of subjects: 136

Group type: COMPARATOR
Intervention: Printed epilepsy educational material
Number of subjects: 136
Study: 22586631

Group type: EXPERIMENTAL
Intervention: HPV16/18 vaccine
Number of subjects: 7466
Study: 19326811

Group type: EXPERIMENTAL
Intervention: Piper longum (15 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Piper longum (30 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Dextrin placebo
Number of subjects: 32
Study: 16377058

Group type: EXPERIMENTAL
Intervention: Artificial ventilation performed in isolation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CPR alone
Number of subjects: 36

Group type: COMPARATOR
Intervention: CPR and CPR+AED
Number of subjects: 36
Study: 15298338

Group type: EXPERIMENTAL
Intervention: Insulin detemir/insulin aspart
Number of subjects: 595
Study: 11515348

Group type: EXPERIMENTAL
Intervention: Lansoprazole suspension (30 mg via nasogastric tube)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lansoprazole intact capsule (30 mg orally)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lansoprazole suspension
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lansoprazole intact capsule
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lansoprazole suspension and intact capsule
Number of subjects: 36
Study: 10351117

Group type: COMPARATOR
Intervention: LW 50020 (Luivac; Paspat oral), taken once daily for two periods of 4 weeks each, with a treatment-free interval of 4 weeks.
Number of subjects: 0
Study: 7845560

Group type: EXPERIMENTAL
Intervention: Internally-controlled orienting using central informative cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Externally-controlled orienting using peripheral non-informative cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of altitudinal neglect
Number of subjects: 0
Study: 3394768

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection in upper eyelids
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline injection in lower eyelids
Number of subjects: 26
Study: 30630800

Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (DEX)
Number of subjects: 92
Study: 27234929

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 500

Group type: COMPARATOR
Intervention: Manual Small-Incision Cataract Surgery (MSICS)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Higher baseline IOP
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: AOD500 widening
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Baseline AOD500
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Baseline anterior chamber depth
Number of subjects: 500
Study: 25257686

Group type: EXPERIMENTAL
Intervention: Experimental AmF/SnF2 mouth rinse A
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Experimental AmF/SnF2 mouth rinse B
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Experimental AmF/SnF2 mouth rinse C
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Phenolic/essential oil rinse D
Number of subjects: 28

Group type: COMPARATOR
Intervention: Water control E
Number of subjects: 28
Study: 24621971

Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg
Number of subjects: 553

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 3 g/day
Number of subjects: 553
Study: 21149427

Group type: EXPERIMENTAL
Intervention: HEPA air cleaners
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control (inactive HEPA air cleaners)
Number of subjects: 225
Study: 18367956

Group type: EXPERIMENTAL
Intervention: Bolus recombinant factor VIII (rFVIII) 25 to 50 IU/kg given 6, 14, 24, 36, 48, and 60 hours after loading dose
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Continuous infusion of recombinant factor VIII (rFVIII) 3 to 4 IU/kg per hour for 48 hours, followed by a bolus of 25 IU/kg at 60 hours
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Loading dose of 100 IU/kg factor IX followed by bolus of 50 IU/kg at 3, 15, 27, and 48 hours
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Midazolam and fentanyl used in the first 8 patients
Number of subjects: 14
Study: 17138770

Group type: EXPERIMENTAL
Intervention: Mifepristone, 5 mg daily for 26 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo for 26 weeks
Number of subjects: 42
Study: 14616871

Group type: EXPERIMENTAL
Intervention: Hydrolysed rice formula (HRF)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned but implied as part of the double-blind study)
Number of subjects: 18
Study: 10601119

Group type: EXPERIMENTAL
Intervention: Saline infusion (750 mL)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Saline infusion (150 mL)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Glucose solution (750 mL)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline infusion (in controls)
Number of subjects: 26
Study: 8911338

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (3 minutes of aortic crossclamping followed by 2 minutes of reperfusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no preconditioning, 5 minutes of bypass)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Number of subjects: 20
Study: 2262647

Group type: EXPERIMENTAL
Intervention: PGF2 alpha
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prostaglandin D2
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All other substances (except PGF2 alpha)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All substances (except methacholine)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prostaglandins (D2 and F2 alpha)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All substances
Number of subjects: 20
Study: 638119

Group type: EXPERIMENTAL
Intervention: Daily supplements of 20-30 mg inorganic iron as ferrous sulphate for 3.5, 7, and 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily requirements of energy and protein, plus 5 microgram cyanocobalamin and 200 microgram folic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fe supplementation
Number of subjects: 0
Study: 30944078

Group type: EXPERIMENTAL
Intervention: Anatomical model of the knee/shoulder joint
Number of subjects: 52

Group type: COMPARATOR
Intervention: Verbal explanation without a model
Number of subjects: 52
Study: 25695618

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 485

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 485

Group type: COMPARATOR
Intervention: Various cohorts
Number of subjects: 485
Study: 23949018

Group type: EXPERIMENTAL
Intervention: Filtek silorane with silorane system adhesive (FS/SSA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ceram X mono with Clearfil SE (CXM/CSE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ceram X mono with XP bond (CXM/XPB)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 24
Study: 22051162

Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Voglibose
Number of subjects: 50
Study: 19348538

Group type: EXPERIMENTAL
Intervention: Resting respiratory sinus arrhythmia (RSAREST)
Number of subjects: 80
Study: 17469936

Group type: EXPERIMENTAL
Intervention: Modafinil (1.75 mg/kg, 3.50 mg/kg, or 7.00 mg/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: d-Amphetamine (0.035 mg/kg, 0.070 mg/kg, 0.140 mg/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 15243523

Group type: EXPERIMENTAL
Intervention: UV exposure
Number of subjects: 14
Study: 12478328

Group type: EXPERIMENTAL
Intervention: Ciclopiroxolamine 1% cream
Number of subjects: 189

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 189
Study: 9809846

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (100 mg x kg(‐1) administered at 0, 30, 60, and 90‐min post‐race)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: In vitro studies with glutamine
Number of subjects: 16
Study: 7654790

Group type: EXPERIMENTAL
Intervention: Pre-schizophrenic boys at age 7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-schizophrenic boys at age 11
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-schizophrenic girls at age 11
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-affective psychotic boys at age 7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-affective psychotic boys at age 11
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-schizophrenics at ages 7, 11, and 16
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schizophrenics-to-be at age 7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schizophrenics-to-be at age 16
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Females with non-psychotic diagnoses at age 11
Number of subjects: 0
Study: 3148282

Group type: EXPERIMENTAL
Intervention: 20-component extract
Number of subjects: 39

Group type: COMPARATOR
Intervention: 2-component extract
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study: 29680102

Group type: EXPERIMENTAL
Intervention: Recurrent VTE (rVTE)
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Bleeding events
Number of subjects: 883
Study: 28031044

Group type: EXPERIMENTAL
Intervention: MediMind
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Autogenic Training
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 183
Study: 25703086

Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg once-daily plus asunaprevir 100 mg twice-daily, with weekly peginterferon alfa-2a and weight-based ribavirin for 24 weeks
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Daclatasvir plus asunaprevir and peginterferon/ribavirin
Number of subjects: 398
Study: 24319685

Group type: EXPERIMENTAL
Intervention: Integrated arterial line filter (Group In)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nonintegrated arterial line filter (Group NIn)
Number of subjects: 36
Study: 20965319

Group type: EXPERIMENTAL
Intervention: Synbiotic product containing Lactobacillus gasseri CHO-220 and inulin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 18221638

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids supplemented diet (EPA + DHA, enriched in salmon 150 g/day, 3 times/week)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Salmon diet (150 g/day, 3 times/week)
Number of subjects: 35
Study: 20577971

Group type: EXPERIMENTAL
Intervention: Positive depression screen during hospitalization
Number of subjects: 738

Group type: COMPARATOR
Intervention: No depression (control group)
Number of subjects: 738
Study: 16313140

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 50 mg caffeine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 100 mg caffeine
Number of subjects: 48
Study: 11568790

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 125 mg intramuscularly
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg orally
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Overall efficacy
Number of subjects: 95
Study: 9783928

Group type: EXPERIMENTAL
Intervention: Sequential therapy with mitomycin C (40 mg) followed by BCG (6 weekly instillations)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Mitomycin C only (10 weekly instillations)
Number of subjects: 182
Study: 7848896

Group type: EXPERIMENTAL
Intervention: Immediate-release isosorbide dinitrate (ISDN) 15-120 mg in a qid regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asymmetric tid therapy with 30 mg of ISDN (7 a.m., 1 p.m., and 6 p.m.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asymmetric bid therapy with ISDN at 7 a.m. and noon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate-release isosorbide-5-mononitrate (IS-5-MN) 10 and 20 mg given bid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Once-daily controlled-release IS-5-MN 120 and 240 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asymmetric bid immediate-release IS-5-MN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Once-daily controlled-release IS-5-MN
Number of subjects: 0
Study: 3140580

Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate (17HPC, Proluton Depot) 500 mg intramuscularly weekly for 6-16 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate (17HPC) when pregnancy was suspected
Number of subjects: 40

Group type: COMPARATOR
Intervention: 17 alpha-hydroxyprogesterone caproate (17HPC) 500 mg intramuscularly weekly
Number of subjects: 40

Group type: COMPARATOR
Intervention: 17 alpha-hydroxyprogesterone caproate (17HPC) 250 mg intramuscularly weekly
Number of subjects: 40

Group type: COMPARATOR
Intervention: Contraceptive pill (Microgynon)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 17HPC
Number of subjects: 40
Study: 31718087

Group type: EXPERIMENTAL
Intervention: Mindfulness-based IARA Model® training
Number of subjects: 497

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 497
Study: 30036596

Group type: EXPERIMENTAL
Intervention: Patients with ACE inhibitor-associated angioedema
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE inhibitor-treated controls
Number of subjects: 0
Study: 26871954

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (1 ml of 40 mg/ml methylprednisolone dissolved in 4 ml lidocaine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo injection (1 ml isotonic saline mixed with 4 ml lidocaine)
Number of subjects: 100
Study: 24652032

Group type: EXPERIMENTAL
Intervention: SC with iPad
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard Counseling (SC)
Number of subjects: 90
Study: 22708259

Group type: EXPERIMENTAL
Intervention: Rapid titration (initial dosage 100 mg/day increased by 100-200 mg at weekly intervals)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Slow titration (initial dosage 50 mg/day increased in 50 mg/day increments at weekly intervals)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Slow titration
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Rapid titration
Number of subjects: 183
Study: 19461385

Group type: EXPERIMENTAL
Intervention: FES cycling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive cycling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrical stimulation exercise without cycling
Number of subjects: 0
Study: 17167261

Group type: EXPERIMENTAL
Intervention: Fluoride Varnish (FV)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fluoride Varnish with toothbrush abrasion (FV‐er+abr)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group with erosion only (C‐er)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group with erosion and toothbrush abrasion (C‐er+abr)
Number of subjects: 11
Study: 15076242

Group type: EXPERIMENTAL
Intervention: Nucleoside analogue treatment; venous lactate measured according to AACTG guidelines.
Number of subjects: 83
Study: 11685979

Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 10
Study: 9669015

Group type: EXPERIMENTAL
Intervention: Hypoallergen tape (group T)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Chloromycetin ointment (group O)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 150
Study: 7836027

Group type: EXPERIMENTAL
Intervention: High-intensity training for 6 weeks (60 min twice a week) in RA-TG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-intensity training (home-training) for another 6 months in RA-TG
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy subjects (healthy-TG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CG) for both RA and healthy subjects
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Comparison of beta-EP levels between RA-TG and healthy-TG after training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Comparison of beta-LPH levels between RA-TG and healthy-TG after training
Number of subjects: 30
Study: 3278390

Group type: EXPERIMENTAL
Intervention: Radiation concurrent with cisplatinum
Number of subjects: 5500

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 5500

Group type: EXPERIMENTAL
Intervention: Carbogen (95% O2 and 5% CO2) breathing or misonidazole during radiotherapy
Number of subjects: 5500

Group type: EXPERIMENTAL
Intervention: Radiosensitizer SR 2508
Number of subjects: 5500

Group type: EXPERIMENTAL
Intervention: Split-course irradiation
Number of subjects: 5500

Group type: EXPERIMENTAL
Intervention: Twice a day irradiation with 120 cGys up to 6,000 cGys
Number of subjects: 5500
Study: 29882318

Group type: EXPERIMENTAL
Intervention: FIFA 11 for Health intervention (11-week program, 2 sessions/week of 45 minutes)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: FIFA 11 for Health intervention
Number of subjects: 392

Group type: COMPARATOR
Intervention: Control group (regular activities)
Number of subjects: 392
Study: 28065181

Group type: EXPERIMENTAL
Intervention: Healthier snack bar (consumed for 6 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Delayed receipt of healthier snack bar (control group)
Number of subjects: 28
Study: 24836961

Group type: EXPERIMENTAL
Intervention: T100/eFlow
Number of subjects: 58

Group type: COMPARATOR
Intervention: TNS/PARI LC PLUS
Number of subjects: 58
Study: 23184140

Group type: EXPERIMENTAL
Intervention: Biological material TOT (PELVILACE® TO)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Synthetic material TOT (ALIGN®TO Urethral Support System)
Number of subjects: 100
Study: 20189705

Group type: EXPERIMENTAL
Intervention: ALS-qualified anaesthetist
Number of subjects: 36

Group type: COMPARATOR
Intervention: ALS-qualified non-anaesthetist
Number of subjects: 36
Study: 18394162

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated; DrotAA) at a dosage of 24 mug/kg per hour for 96 hours
Number of subjects: 2225

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated; DrotAA)
Number of subjects: 2225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2225
Study: 16797936

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12419011

Group type: EXPERIMENTAL
Intervention: Mortality salience condition
Number of subjects: 312

Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 312
Study: 10613302

Group type: COMPARATOR
Intervention: RT plus PCV
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: RT/BUdR plus PCV
Number of subjects: 281
Study: 7486780

Group type: EXPERIMENTAL
Intervention: Initial screening by senior surgical staff
Number of subjects: 0
Study: 1785247

Group type: EXPERIMENTAL
Intervention: Oral atropine 0.03 mg/kg (Group A)
Number of subjects: 58

Group type: COMPARATOR
Intervention: i.v. glycopyrrolate 0.005 mg/kg (Group G)
Number of subjects: 58
Study: 7211903

Group type: EXPERIMENTAL
Intervention: Teflon catheters
Number of subjects: 954

Group type: COMPARATOR
Intervention: Steel needles
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: Overall complications
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: Infiltration
Number of subjects: 954
Study: 31860598

Group type: EXPERIMENTAL
Intervention: Two-handed jaw thrust
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional intubation with sham jaw thrust
Number of subjects: 106